By Rishika Sadam and Sriparna Roy HYDERABAD, Feb 17 (Reuters) - Indian drugmaker Dr Reddy’s Laboratories hopes to launch a ...

Nomura India said DRL's acquisitions over the past five years may contribute around one-quarter of the company’s revenues in ...

Dr. Reddy's Laboratories Ltd. 500124 shares slipped 1.51% to 1,255.70 Indian rupees Tuesday, on what proved to be an ...

Dr. Reddy’s announces USFDA acceptance to review its Biologics License Application (BLA) for proposed interchangeable biosimilar, Abatacept.

Firms including Bank of India, Jindal Stainless, PNB Housing Finance, and Tata Communications are also to release their ...

On Wednesday, shares of Dr Reddy's slipped 0.32 per cent to settle at Rs 1280.85, down from its previous close of Rs 1285 apiece on the BSE.

Join us on the Dr Reddys Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay ...

Dr. Reddy's Laboratories Ltd. closed 7.50% below its 52-week high of 1,377.95 rupees, which the company reached on June 12th.

Dr. Reddy’s Laboratories (RDY) stock is in focus as the FDA agrees to review its biosimilar targeting Bristol Myers' (BMY) ...

SHREVEPORT, La. (KTAL/KMSS) – Dr. Reddy’s Laboratories, a global pharmaceutical company, recently closed in early 2025 due to business and financial decisions. U.S. Senator Bill Cassidy, M.D. (R-LA), ...

Dr Reddy’s Laboratories plans to introduce a generic version of Wegovy in India at a significantly reduced price. With the ...

Dr Reddy’s Laboratories has acquired the trademarks Progynova and CycloProgynova, along with related assets for India, from ...